Black Diamond Therapeutics Inc BDTX

US Biotechnology

$1.61 ▼ -13.44% ($-0.25)

🧊 52W Low ⬇️ Below Yest. Low 🎢 High Beta

Open $1.89

Prev Close $1.86

Day Range $1.59 – $1.91

52W Range $1.60 – $4.94

Market Cap $106.86M

P/E (TTM) 4.88

Beta 3.48

EPS (TTM) $-0.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-01-30
Shares Out.	57,450,000
Website	blackdiamondtherapeutics.com/ ↗
Phone	13026587581
Employees	21
Revenue	$0
Gross Profit	$0
Net Income	-$9.9M
Free Cash Flow	-$32.8M
Total Assets	$125.0M
Total Liabilities	$28.9M
Equity	$96.1M

About Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Black Diamond Therapeutics Inc is a publicly traded company under the ticker symbol BDTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.